An Open-Label, Multicenter Study to Assess the Safety of RO5185426 (Vemurafenib) in Patients With Metastatic Melanoma
An Open-Label, Multicenter Study to Assess the Safety of RO5185426 (Vemurafenib) in Patients With Metastatic Melanoma
This multi-center study evaluates the safety and efficacy of vemurafenib in participants with BRAF V600 mutation-positive, surgically incurable, and unresectable Stage IIIC or IV (American Joint Committee on Cancer [AJCC]) metastatic melanoma.
Inclusion Criteria:
Exclusion Criteria:
Wodonga, New South Wales 3690, Australia
Woolloongabba, Queensland 4102, Australia
Rio de Janeiro, Rio de Janeiro 20230-130, Brazil
Sofia, 1756, Bulgaria
Vancouver, British Columbia V5Z 4E6, Canada
Toronto, Ontario M5G 2M9, Canada
Montreal, Quebec H3T 1E2, Canada
Medellin-Antioquia, Colombia
Prague, 128 00, Czechia
Berlin, 12200, Germany
Dresden, 01307, Germany
Frankfurt, 60596, Germany
Göttingen, 37075, Germany
Hamburg, 20246, Germany
Leipzig, 04103, Germany
Magdeburg, 39120, Germany
München, 80337, Germany
Recklinghausen, 45657, Germany
Würzburg, 97080, Germany
New Delhi, National Capital Territory of Delhi 110085, India
Hafia, 3109601, Israel
Meldola, Emilia-Romagna 47014, Italy
Udine, Friuli Venezia Giulia 33100, Italy
Rome, Lazio 00167, Italy
Genoa, Liguria 16132, Italy
Pisa, Tuscany 50126, Italy
Vilnius, 08661, Lithuania
Skopje, 1000, North Macedonia
Arequipa, 04001, Peru
Saint Petersburg, Sankt-Peterburg 197758, Russia
Saint Petersburg, 197022, Russia
Santander, Cantabria 39008, Spain
A Coruña, La Coruña 15006, Spain
Las Palmas de Gran Canaria, Las Palmas 35016, Spain
Cartagena (Murcia), Murcia 30202, Spain
Oviedo, Principality of Asturias 33011, Spain
Bornova, İ̇zmi̇r, 35100, Turkey (Türkiye)
Newcastle upon Tyne, NE7 7DN, United Kingdom